Despite Declining Q4 Revenues, Transgenomic to Develop Assays in 'Key Markets' | GenomeWeb

Transgenomic reported a 6 percent decline in fourth-quarter 2008 revenues last week, but company officials sought to reassure investors in a difficult economic climate by highlighting development plans for several new assays in "key markets."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.